One person in seven has the antibodies required to fight coronavirus according to new research.
Researchers at Imperial College London have discovered that 13.9 per cent of the British population has the antibodies required to fight coronavirus, adding to the populations immunity to the virus as the vaccine roll out continues.
Blood tests on more than 154,000 people across England revealed the new figures, which showed that between January 26 and February 8 – just past the peak of the second wave – that one in seven had antibodies.
The researchers who have monitored the antibody levels within the population for several months have now revealed their findings for the first time since the roll out of the vaccine.
To sign up for the Hull Live newsletter, click here.
It was found that over 17,000 people of those who took part in the study had already received at least one dose of the vaccine while 88 per cent of people over the age of 80 tested positive for antibodies after two doses of the Pfizer-BioNTech vaccine.
96 per cent of those under the age of 60 and 100 per cent in those aged under 30 also tested positive for the antibodies.
Prof Helen Ward, the lead researcher, said: “Most people develop a detectable antibody response after one dose. Our findings suggest that it is very important for people to take up the second dose when it is offered.”
The study also showed the confidence in the vaccine from the public, with 92 per cent of participants accepting or planning to accept the jab.
It comes as it was today reported that the Pfizer vaccine provides strong protection against Covid-19 symptoms and severe disease after two doses, according to the first large-scale peer-reviewed study of the effectiveness of the vaccine.
Although, the study also found that there is markedly lower protection for those who have only received dose one of the vaccine.
The study by Israel’s Clalit Research Institute was conducted in collaboration with researchers from Harvard University and found that two doses of the Pfizer vaccine reduced coronavirus symptoms by 94 per cent and severe disease by 92 per cent.
A person receiving only a single dose reduced symptoms by just 57 per cent and severe disease by 62 per cent after three weeks.